For decades, doctors treated diabetes and dementia as separate problems. But a growing body of research reveals they are deeply connected, with one condition dramatically raising the risk of the other and both sharing the same underlying mechanism: the brain's struggle to use energy.
People with diabetes face roughly 60% higher odds of developing dementia than those without the disease. The risk climbs even higher for those who experience frequent episodes of low blood sugar, which is tied to a 50% increase in cognitive decline. The connection works both ways, too. Those diagnosed with Alzheimer's often show signs of pre-diabetes, with elevated fasting blood glucose levels even if they have never been diagnosed with diabetes itself.
At the heart of this two-way street lies insulin resistance. In type 2 diabetes, cells throughout the body stop responding properly to insulin, leaving excess glucose circulating in the blood. But the brain is not immune to this problem. When insulin resistance takes hold in the brain, neurons lose their ability to absorb and use glucose efficiently for energy. The brain consumes roughly 20% of the body's energy despite being only 2% of body weight, making this glucose shortage particularly devastating. Some researchers have begun calling this state "type 3 diabetes" in the brain.
The genetic architecture underlying Alzheimer's risk points to the same culprit. The APOE4 gene variant, which carries the highest genetic risk for Alzheimer's, works by reducing insulin sensitivity. It traps the insulin receptor inside the cell, preventing it from functioning properly and blocking the brain's ability to respond to insulin signals.
Diabetes inflicts additional damage through the body's blood vessels. High or fluctuating blood glucose levels injure the delicate vessels that feed the brain, cutting off blood flow and oxygen. Diabetes also weakens the brain's protective barrier, allowing harmful substances to seep in and trigger inflammation. Both reduced blood flow and brain inflammation are strongly linked to dementia development.
The discovery of this connection has not gone unnoticed by drug developers. Memantine, now used to treat moderate to severe Alzheimer's, was originally developed as a diabetes medication. It failed to control blood glucose but showed unexpected benefits for brain function, hinting at how diabetes research might unlock treatments for neurological disease.
Several diabetes medications show promise in reducing dementia risk. Metformin, the world's most widely prescribed diabetes drug, crosses the blood-brain barrier and may lower inflammation in the brain itself. Studies suggest that people with diabetes who take metformin are less likely to develop dementia, and those who stop taking it see their risk climb again. The drug is now being tested in people without diabetes to see if it offers broader brain protection.
Newer weight-loss drugs are showing even stronger results. GLP-1 receptor agonists like semaglutide lower blood glucose and support weight loss, and people with diabetes taking these drugs have significantly lower dementia risk. In some studies, GLP-1 drugs outperformed metformin at reducing dementia risk. Two major clinical trials, Evoke and Evoke Plus, are now testing oral semaglutide directly in people with mild cognitive impairment or early Alzheimer's.
SGLT2 inhibitors, another class of diabetes medication that works by flushing excess sugar through the urine, appear to offer even stronger dementia protection than GLP-1 drugs. They seem to lower dementia risk by reducing brain inflammation, opening a new avenue for treatment.
Direct insulin therapy to the brain itself is also under investigation. Researchers have developed nasal sprays that deliver insulin straight to brain tissue while minimizing effects on blood sugar levels. Early studies suggest these sprays may improve memory and reduce brain shrinkage, though delivery remains inconsistent and long-term safety has not been established.
The pharmaceutical toolbox for diabetes now contains more than 50 different medicines across at least 13 drug classes, each working through different mechanisms to lower blood sugar, improve insulin sensitivity, or reduce inflammation. As researchers study these medications more closely, an unexpected benefit is emerging: protecting brain health during aging may turn out to be a valuable side effect of treating diabetes itself.
Whether these drugs can reduce dementia risk in people without diabetes remains an open question, but the evidence suggests that managing blood sugar and insulin function safeguards far more than the heart and kidneys. It protects the brain.
Author Jessica Williams: "The diabetes-dementia link reframes how we think about blood sugar control, not as a metabolic issue isolated from the brain, but as foundational to cognitive longevity."
Comments